Titan Pharmaceuticals
TTNP
TTNP was delisted on the 1st of October, 2025.
39 hedge funds and large institutions have $14.3M invested in Titan Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 7 increasing their positions, 2 reducing their positions, and 1 closing their positions.
2,400% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 1
515% more call options, than puts
Call options by funds: $1.91M | Put options by funds: $311K
440% more capital invested
Capital invested by funds: $2.65M → $14.3M (+$11.7M)
250% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 2
160% more funds holding
Funds holding: 15 → 39 (+24)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$2.88M |
| 2 |
State Street
Boston,
Massachusetts
|
+$1.77M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.58M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$980K |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$767K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SIM
Spark Investment Management
New York
|
-$298K |
| 2 |
DADC
D.A. Davidson & Co
Great Falls,
Montana
|
-$170K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$26K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AG
51
Advisor Group
Phoenix,
Arizona
| $2K | – | – | – |
|
|
52
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$26K | -2 | Closed |
|
TTNP Hedge Fund Activity: Q2 2016 in Review
39 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Titan Pharmaceuticals (TTNP) for Q2 2016, worth a combined $14.3M — up 440% from $2.65M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new TTNP positions and 1 closed out — a net gain of 24 holders — while 7 added to existing stakes and 2 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $2.88M. The largest seller was Spark Investment Management, cutting an estimated $298K.
- 39 institutional investors held Titan Pharmaceuticals (TTNP) as of Q2 2016, up from 15 in Q1 2016.
- Funds reported $14.3M of Titan Pharmaceuticals stock for Q2 2016, up 440% quarter-over-quarter.
- 25 funds opened new Titan Pharmaceuticals positions in Q2 2016 and 1 closed out, a net change of +24 holders.
- The largest Titan Pharmaceuticals buyer in Q2 2016 was BlackRock Fund Advisors, an estimated $2.88M added.
- The largest Titan Pharmaceuticals seller in Q2 2016 was Spark Investment Management, an estimated $298K sold.
Based on aggregated 13F filings for Q2 2016.